OncoSec Medical Incorporated
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, OncoSec Medical Incorporated sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
OncoSec Medical Incorporated: 5 sponsored US clinical trials, none currently recruiting.
OncoSec Medical Incorporated sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 1 trials.
Upper-quartile sponsor footprint
OncoSec Medical Incorporated sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
NCT02531425
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
NCT02345330
Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
NCT01579318
Trial of pIL-12 Electroporation Malignant Melanoma
NCT01502293
IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
NCT01440816
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Therapeutic Areas
How the OncoSec Medical Incorporated early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Melanoma (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
OncoSec Medical Incorporated: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
OncoSec Medical Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this OncoSec Medical Incorporated page
5 registered trials is a research-attention snapshot, not an endorsement of OncoSec Medical Incorporated or any single study.
- None of OncoSec Medical Incorporated's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Melanoma is the condition OncoSec Medical Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. OncoSec Medical Incorporated pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.